A patient with relapsed small-cell lung cancer is unsuitable for re-treatment with the first-line regimen. Severe anthracycline cardiomyopathy makes

Question

A patient with relapsed small-cell lung cancer is unsuitable for re-treatment with the first-line regimen. Severe anthracycline cardiomyopathy makes CAV contraindicated, but oral treatment is feasible. Which statement follows NICE TA184?

Accepted Answer

Use oral topotecan in this setting; intravenous topotecan is not recommended

Answer

Exclude topotecan because first-line regimen re-treatment is unsuitable

Answer

Use intravenous topotecan because oral topotecan was not included in the appraisal

Answer

Use either intravenous or oral topotecan whenever disease relapses after first-line treatment

Answer

Use oral topotecan only after CAV has been given and shown to fail

Second-line SCLC Topotecan — SCE Medical Oncology MCQ

A patient with relapsed small-cell lung cancer is unsuitable for re-treatment with the first-line regimen. Severe anthracycline cardiomyopathy makes CAV contraindicated, but oral treatment is feasible. Which statement follows NICE TA184?